Pacira Biosciences reported preliminary net product sales in 1Q FY21 of Exparel (bupivacaine liposome injectable suspension) and iovera of $114.7 million and $3.
In a research note issued today, Wedbush analyst Liana Moussatos (TipRanks #1) reiterated an Outperform rating on Pacira (NASDAQ:PCRX) and slightly raised her price …
In a report issued today, analyst Liana Moussatos of Wedbush reiterated an Outperform rating on Pacira Pharmaceuticals (NASDAQ:PCRX) with a $117 price target, as the company recently announced …